Understanding the process of carcinogenesis is key to developing therapies which might interrupt or reverse tumor onset and progression. Cell growth and death signals are dependent not only upon molecular mechanisms within a cell but also upon external stimuli such as hormones, cell ± cell signaling, and extracellular matrix. Mouse models can be used to dissect these complex processes, to identify key signaling pathways operating at dierent stages of tumorigenesis, and to test the strength of speci®c interventions. In the WAP-TAg mouse model, carcinogenesis is initiated by expression of the Simian Virus 40 T antigen (TAg). TAg expression is triggered by hormonal stimulation, either during estrus or pregnancy. Breast adenocarcinomas (ranging from well to poorly dierentiated) develop in 100% of the female mice by approximately 8 ± 9 months of age. Three distinct stages of tumorigenesis are easily identi®ed: an initial proliferation, hyperplasia, and adenocarcinoma. The mean time to ®rst palpable tumor in mice which undergo at least one pregnancy is 6 months. The tumorigenic process is marked by a competition between proliferation and apoptosis and is characterized by cellular acquisition of genetic mutations and increased stromal ®brosis. Protein levels of cell cycle control genes cyclin D1, cdk2, and E2F-1 are increased in these adenocarcinomas. c-Fos protein levels are slightly increased in these cancers, while c-Jun levels do not change. Hormonal exposure alters progression. Estrogen plays a role during the early stages of oncogenesis although the growth of the resulting adenocarcinomas is estrogen-independent. Transient hormonal stimulation by glucocorticoids that temporarily increases the rate of cell proliferation results in tetraploidy, premature appearance of irreversible hyperplasia, and early tumor development. Tumor appearance also can be accelerated through over expression of the cell survival protein, Bcl-2. Bcl-2 over expression not only reduces apoptosis during the initial proliferative process but also decreases the total rate of cell proliferation. This block in cell proliferation is lost selectively as the cells transition to adenocarcinoma. The WAP-TAg model can be utilized to investigate how the basic processes of cell proliferation, apoptosis, DNA mutation, and DNA repair are modi®ed by external and internal signals during mammary oncogenesis.
Introduction
Breast cancer is one of the most common forms of cancer among women both in the United States and worldwide (Newcomb, 1997) . Development of the disease is a multistep process proceeding from an initiated cell(s) through hyperplasia, to malignancy and depends upon the successive activation of oncogenes and inactivation of tumor suppressor genes. Hormonal factors both endogenous and exogenous in¯uence this process. Mouse models can be used to dissect how dierent factors collaborate during the process of mammary carcinogenesis.
In the WAP-TAg mouse model of breast cancer, carcinogenesis is initiated by expression of Simian Virus 40 large T antigen (TAg)
Introduction of a WAP-TAg transgene into a mouse targets the expression of TAg speci®cally to mammary epithelial cells (Tzeng et al., 1993; Li et al., 1996a,b; Santarelli et al., 1996) . In the transgenic line presented here, 100% of the female mice develop mammary carcinoma by the age of 6 months if they undergo at least one pregnancy. The process of tumorigenesis is marked by a competition between proliferation and apoptosis. When TAg is expressed during the ®rst pregnancy it triggers both cell proliferation and p53-independent apoptosis ( Figure 1a ) (Li et al., 1996a; Tzeng et al., 1996) . The rate of cell proliferation remains relatively high throughout tumorigenesis, but the incidence of apoptosis falls as the cells transition to hyperplasia and adenocarcinoma (Furth et al., 1999) . After the ®rst parturition, the mammary glands from transgenic mice involute normally with respect to apoptosis and tissue remodeling ; however, after two to three pregnancies, the glands are not fully remodeled following involution (Figure 2 ). The lobule-alveolar structures in the TAg mice that resist remodeling are hyperplastic. Some but not all of the hyperplasias progress to carcinoma in situ and then to adenocarcinoma (Figure 1b) . The adenocarcinomas which develop in the TAg mice range from well to poorly dierentiated ( Figure 3 ) (Furth et al., 1999) .
SV40 TAg does not initiate human breast cancer, but it does dysregulate some of the same cellular pathways that are dysfunctional in human breast cancer TAg binds to p53, the Retinoblastoma protein (pRb), and related family members (p107, p130) and functionally inactivates them (Meitz et al., 1992; Dyson et al., 1989) . Mutation of p53 is described in up to 40% of human breast cancers and inactivation of pRb and other cell cycle control proteins has also been described (Horak et al., 1991; Lee et al., 1988) . As is likely for the majority of human breast tumors, exposure to the initiating oncoprotein is insucient for full progression to breast malignancy (Hahn et al., 1999) . Rather, time-related events which include exposure to hormonal stimulation, subsequent changes in the rate of cell proliferation or apoptosis, and acquisition of additional genetic mutations are required for development of breast cancer. In the WAP-TAg mouse model, expression levels of speci®c cell survival and cell cycle control proteins increase as the cells transition from the initial proliferative phase through hyperplasia to adenocarcinoma. Cyclin D1, cdk2, and E2F-1 protein levels increase signi®cantly, whereas, less dramatic elevations in c-Fos expression are found (Figure 4b ± d) . Bcl-x long , Bax, Bag-1 (Figure 4e ) and Bad (Furth et al., 1999) protein expression levels are also higher in the adenocarcinomas. In contrast, expression levels of c-Jun and cyclin E protein do not change signi®cantly at dierent stages of carcinogenesis. Secondary mutations appear to contribute to the process of TAg-induced carcinogenesis (Ewald et al., 1996) . Ki-ras ampli®cations have been found in approximately 10% of TAg-induced mammary adenocarcinomas (M Li, M Liyanage, T Ried and PA Furth, unpublished results) . It is anticipated that additional mutations (including ampli®cations) will be identi®ed with further study of the TAg animals. Estrogen is essential for mammary ductal growth during the developmental stages which extend from puberty to sexual maturity and may also play a role in the pathogenesis of human breast cancer. Progesterone is required for the formation of lobule-alveolar structures during pregnancy. Intact prolactin signaling pathways are required for normal mammary gland development during pregnancy and also contribute to lactogenesis . Glucocorticoid is an important lactogenic hormone required for maximal production of milk during lactation (Topper and Freeman, 1980) and may additionally contribute to cell survival. Physiological levels of lactogenic hormones, including glucocorticoid, do not block the apoptosis of mammary epithelial cells (Li et al., 1997) , but supraphysiological levels of exogenously administered glucocorticoid can inhibit mammary epithelial cell apoptosis (Feng et al., 1995) and block degradation of basement membrane (Lund et al., 1996) .
Chronic changes in estrogen exposure alter early but not the late stages of carcinogenesis in the WAP-TAg model
Changes in cyclic estrogen exposure can either accelerate or retard the appearance of ®rst palpable mammary tumor . In our laboratory, ovariectomy (ovx) of TAg mice after the ®rst pregnancy lengthened the mean time to ®rst palpable tumor by 9 weeks (ovx: 35+6 weeks (wk), n=5; control: 26+4 wk, n=21; (P=0.05)). Chronic estrogen exposure in ovariectomized mice (n=5) following the ®rst pregnancy shortened the mean time to ®rst palpable tumor by 5 weeks as compared to placebo-treated controls (n=4) (P=0.05).
In contrast to the eect of estrogen on tumor development, growth of established mammary adenocarcinomas is estrogen-independent. Adenocarcinomas continue to grow at a mean rate of 0.4 cm 3 /week when mice were ovariectomized at the time of ®rst palpable tumor and an average of two new tumors appeared per mouse over the next month.
Eects of transient exposure to estrogen, prolactin, progesterone, and glucocorticoid on cell survival and oncogenesis in the WAP-TAg mouse model Transient exposure to increased levels of glucocorticoids induces cell proliferation and the rapid develop- Figure 2 After serial pregnancies, mammary glands from WAPTAg mice are not fully remodeled during involution. Note the increased tissue density in the gland from the WAP-TAg transgenic mouse at day 13 of involution following the third pregnancy as compared to the non-transgenic control gland at the same timepoint. Whole mounts of fourth (inguinal) glands The eect of glucocorticoid is dose-dependent; in the WAP-TAg mice, the maintenance of lactogenic hormone stimulation through suckling does not produce hyperplasia whereas exogenous glucocorticoid does ( Figure 5f ). Similarly, in normal, non-transgenic control mice, exposure to lactogenic hormones does not block apoptosis (Li et al., 1997) , while high levels of glucocorticoids can block both apoptosis and tissue remodeling (Feng et al., 1995; Lund et al., 1996) . In WAP-TAg mice apoptosis of mammary epithelial cells and involution proceed normally following the ®rst parturition with the gland fully remodeling ( Figure 6a ; Li et al., 1996b) . However, mice exposed to glucocorticoid at the time of the ®rst involution develop a degree of hyperplasia ( Figure   6b ) comparable to that seen after three pregnancies in untreated WAP-TAg mice ( Figure 6c ). Cell cycle analyses of the glucocorticoid-treated hyperplastic tissue demonstrate increased S phase entry and tetraploidy (Figure 6d ± e; Table 1 ). There is no signi®cant change in the percentage of apoptotic cells in the glucocorticoid-treated WAP-TAg mice as compared to control WAP-TAg mice that are suckled to maintain lactogenic hormone stimulation (gluc-exp: 5.9% vs control: 5.1%). The glucocorticoid-treated mice exhibit accelerated tumor development and demonstrate a signi®cant increase in the number of tumors per mouse using a log-rank test (P=0.0006) (Figure 7 ).
Glucocorticoid-exposed WAP-TAg mice as a model for reversible and irreversible hyperplasia
The glucocorticoid-treated WAP-TAg mice can be exploited as a model for reversible and irreversible mammary hyperplasia. Following transient glucocorticoid exposure, the hyperplastic cells within the mammary tissue begin to undergo apoptosis with partial hyperplastic tissue regression (Figure 8a ± c).
In the 30 days following transient glucocorticoid exposure, 95% of the multi-layered hyperplastic alveoli regress to a single cell layered alveoli; however, 5% of the tissue does not fully regress and foci of abnormal tissue that resemble carcinoma in situ persist ( Figure 8d ). These persistent foci are likely to be responsible for the accelerated tumor development and increased tumor multiplicity found in the glucocorticoid-treated TAg mice ( Figure 7 ).
Development of more eective approaches to the treatment of pre-malignant lesions is an important area of focus for breast cancer biologists. This model of reversible and irreversible hyperplasia progressing to cancer can be utilized to explore how dierent therapeutic approaches may shift the balance from progression to regression. The model can be used to test agents for their ability to in¯uence mammary hyperplasia regression and prolong or prevent tumor formation. The role of speci®c signaling pathways can also be examined. For example, levels of Stat5 phosphorylation are abnormally high in the glucocorticoid-exposed mammary tissue (M Li, S Ren and PA Furth, unpublished results). Further investigation, including breeding experiments in progress with mice carrying functional deletions of Stat5a and 5b, will reveal if abnormal activation of Stat5 is a contributing factor to more rapid disease progression. The same approach can be applied to investigate other regulatory candidates. Finally, this model can be used with gene array and other technologies to identify known or novel genetic pathways that might contribute to disease reversal or progression.
Expression of Bcl-2 family members and tumorigenesis in the WAP-TAg mouse model
The Bcl-2 gene family, survival of mammary epithelial cells, and breast oncogenesis Bcl-2 and related family members play an important role in survival of normal mammary epithelial cells and imbalanced expression of Bcl-2 family survival and death factors can alter the response to treatment in human breast cancer (Schorr et al., 1999a,b) . Changes in expression patterns of cell survival and cell death factors is one factor that may contribute to development and progression of human breast cancer. The WAP-TAg mouse model can be utilized to explore how speci®c genetic and cellular factors impact on apoptosis and cell proliferation at different stages of the disease. To date we have tested the roles of Bcl-2 over expression, loss of Bax expression, and the combination of Bcl-2 over expression with loss of Bax in this model.
Over expression of Bcl-2 inhibits mitosis at early stages of TAg-induced carcinogenesis but anti-mitotic activity is lost as the cells transition to carcinoma. In contrast, the anti-apoptotic action of Bcl-2 is maintained throughout tumorigenesis Simultaneous over expression of Bcl-2 with TAg in mammary epithelial cells inhibits TAg-induced mitotic activity during the initial proliferative process. Signi®cantly, this activity is lost in mammary adenocarcinomas (Furth et al., 1999) . In contrast, the antiapoptotic action of Bcl-2 transgene persists throughout tumorigenesis. The mechanism responsible for the selective loss of the Bcl-2-directed anti-mitotic activity remains under investigation. One hypothesis is that increased expression levels of speci®c cell cycle control proteins (Figure 4a ) may titrate out or otherwise negate the Bcl-2 inhibitory activity. Interestingly, antiproliferative activity also has been observed in adenocarcinomas triggered by dimethylbenz(a)-anthracene-treated (DMBA) treatment of WAP-Bcl-2 transgenic mice, but this eect is maintained throughout tumorigenesis (Murphy et al., 1999) . The dierent behavior of Bcl-2 in these models may be explained by the type of signaling pathways disrupted. In the WAPTAg model, disruption of p53 function, alteration of the activity of pRb, p107, and p130, and interruption of transforming growth factor-b (TGF-b) function have all been found. While the database is incomplete, activity of at least some of these pathways may be intact in DMBA-induced cancers (Furth et al., 1999) . In the end, as one might predict, simultaneous over expression of Bcl-2 with TAg accelerates the appearance of palpable tumors; in contrast, the appearance of tumors is delayed in the DMBA model.
Interactions between loss of Bax function and gain of Bcl-2 function in the WAP-TAg model WAP-TAg mice with dierent levels of Bax expression were tested for the time to ®rst palpable tumor. Neither partial nor complete loss of Bax function by itself accelerated tumorigenesis in the WAP-TAg mice (Figure 9a) . In contrast, a trend towards delayed tumor development was seen in the WAP-TAg/ Bax7/7 mice. While this requires further investigation, it is possible that this is due to systemic eects secondary to loss of Bax function. Bax7/7 mice are reported to exhibit mammary ductal hypoplasia (Shibata et al., 1999) which could be consistent with TAg H(7.5mg)Inv2d
TAg E2(10ug)Inv2d TAg Pr(2mg)Inv2d
TAg Pl (300mg)Inv2d TAg PBS Inv2d TAg Suck2d The absence of a signi®cant eect on tumorigenesis with either partial or complete loss of Bax expression in the WAP-TAg model could be due to the development of resistance to Bax-induced apoptosis during mammary tumorigenesis. Rates of apoptosis fall from nearly 6% during the initial proliferative phase to approximately 1.5% in the mammary adenocarcinomas of WAP-TAg mice (Furth et al., 1999) . During this transition levels of Bax, Bcl-x long ( Figure 4e ) and Bad protein rise (Furth et al., 1999) . It is possible that the high levels of Bax do not eectively induce apoptosis in tumors due to its interaction with Bcl-x long , which is also highly expressed in these tumors. If that is the case, loss of Bax function by itself might not have a marked eect. Additional experiments will be required to measure the eectiveness of Bax alone in inducing apoptosis at the dierent stages of WAP-TAg-induced 
Glucocorticoid exposed WAP-TAg mice (n=6). Values compared using paired t-tests. P-values are listed
Tumor progression in the WAP-TAg mouse model M Li et al Figure 7 The rapid development of hyperplasia in the glucocorticoid-treated WAP-TAg mice results in both accelerated tumor development and an increase in the total number of tumors per mouse. (a) Percentage of tumor-free mice graphed as a function of age (in weeks). Glucocorticoid-treated (Gluc-exp) WAP-TAg mice: (n=14). Control, unexposed WAP-TAg mice: (n=20). The dierence in the tumor incidence curves was highly signi®cant (P=0.0006). (b) Mean number of tumors in the glucocorticoid-treated WAP-TAg mice was signi®cantly higher than that found in the non-exposed WAP-TAg mice (P50.05 by paired t-test). Tumor multiplicity measured at the time the largest tumor was 1 cm in diameter. Gluc-exp WAP-TAg mice: (n=18). Control WAP-TAg mice: (n=19). Standard deviation indicated H(7.5mg)Inv2d H(7.5mg)Inv13d H(7.5mg)Inv32d H(7.5mg)Inv32d (Figures  9c,d) . Tumors tended to appear at a younger age in the WAP-TAg/WAP-bcl-2/Bax7/7 mice as compared to the WAP-TAg/Bax7/7 mice and the size of these tumors was signi®cantly increased over the average size found in the WAP-TAg mice (P50.008). Gain of Bcl-2 can synergize with loss of Bax during mammary gland involution (Schorr et al., 1999a) .
Summary
The WAP-TAg mouse model can be used to explore how changes in cell proliferation and apoptosis impact on tumorigenesis. One strength of this model is that it can be used to study events during the dierent stages of tumorigenesis, not only its ®nal outcome. The relative contributions of speci®c gene products or signaling pathways to cell proliferation, apoptosis, and mutation can be assessed in a stage-speci®c approach. Underlying mechanisms and the development of early interventions that may be used to halt or retard cancer progression are important focus areas for this model.
Materials and methods
Mouse models, hormone administration, mammary gland biopsies, ovariectomy, and preparation of mammary gland whole mounts Mouse models: Transgenic mice carrying a WAP-TAg hybrid gene and their non-transgenic littermates were used for the bestradiol, prolactin, progesterone, glucocorticoid, and ovariectomy experiments. Non-transgenic and transgenic NMRI mice carrying a WAP-TAg transgene were identi®ed using a polymerase chain reaction (PCR) based approach (Li et al., 1996a) . Transgenic NMRI/C57bl/6/SV129 mice carrying a WAP-TAg transgene and either haploid or complete functional deletion of the Bax gene were identi®ed using another PCR approach (Schorr et al., 1999a) .
Hormone administration Glucocorticoid: Groups of ®ve transgenic and ®ve non-transgenic mice were exposed to exogenous glucocorticoids, on day 18 and the day of parturition of the ®rst pregnancy, by subcutaneous injection Tumor progression in the WAP-TAg mouse model M Li et al of 7.5 mg hydrocortisone (Merck, West Point, PA, USA). Ten mg b-estradiol (Sigma Chemical Co, St Louis, MO, USA) and 2 mg progesterone (Sigma) were administered at the same two timepoints as used for glucocorticoid. Two hundred mg prolactin from sheep pituitary (Sigma) was injected twice per day for 4 days at days 18, 19, and 20 of pregnancy and the day following parturition. b-estradiolslow-release pellets (0.025 mg/pellet, 3 week release) and placebo pellets (Innovative Research of America, Sarasota, FL, USA) were embedded under the back skin lying between the shoulder blades after ®rst parturition for the experiments utilizing pellets. Four days after initial exposure to glucocorticoid and 2 days after parturition, mammary gland biopsies were performed to remove the left side fourth (inguinal) mammary glands as described previously (Li et al., 1996a) . Mice were not allowed to suckle their young; therefore, these glands were collected at day 2 of involution. Control mammary glands were removed from mice that had undergone either 2 days of mammary gland involution or had been suckled for 2 days. After the ®rst biopsy, a second biopsy was performed 13 days later to remove the right side fourth (inguinal) gland and the mice were euthanized 32 days after exposure to glucocorticoids with the remaining mammary glands collected at autopsy. For the acute estrogen, progesterone, and prolactin experiments, mice were euthanized at day 2 of the involution and the mammary glands collected at autopsy. All glands collected were physically divided for histology and protein analyses. Specimens for histology were ®xed in 10% formalin while samples for protein analysis were frozen in liquid nitrogen and stored in 7708C for Western blot analysis.
Ovariectomy Mice were anesthetized with 0.7 ml of 0.175% avertin (Li et al., 1996a) and positioned ventral side down on a dissection board. The fur was shaved o the skin overlying the ovaries and the area was wiped with 70% ethanol. The ovarian fat pads were localized and a small lateral incision was made through the skin and peritoneum above the ovarian fat pad. The fat pad was then grasped with a blunt forceps and taken out of the mouse by careful excision using small scissors. The uterine horn was subsequently replaced into the abdomen and the incision was closed using wound clips. The mouse was wrapped with a disposable laboratory paper towel, placed back in the cage, and observed during recovery.
Whole mount preparation Mammary gland specimens were spread on glass slides and ®xed in Carnoy's solution (100% ethanol : chloroform : glacial acetic acid at 6 : 3 : 1) for at least 1 h at room temperature. Following ®xation, the glands were washed with 70% ethanol for 15 min and water for 5 min. Then the glands were stained in carmine alum solution (1 g carmine (Sigma); 2.5 g aluminum potassium sulfate (Sigma) in 500 ml water) at 48C overnight. The tissue was then dehydrated and mounted on glass using routine methods (Li et al., 1996) . Experimental protocols were approved by the Institutional Animal Care and Use Committees.
Histological examination and in situ detection of programmed cell death
Mammary gland specimens were ®xed in 10% neutral formalin solution and embedded in paran using routine methods (Li et al., 1996) . Five-micrometer tissue sections were used for hematoxylin and eosin staining or for in situ detection of apoptosis using Apoptag (Oncor, Gaithersburg, MD, USA). Histologic specimens were examined under the microscope for the presence or absence of hyperplasia and carcinoma in situ. Reversible and irreversible hyperplasia was characterized by single to multilayered epithelial cells with nuclear atypia organized around a lumen. Irreversible hyperplasia that did not regress during post-pregnancy involution of the gland was surrounded by increased connective tissue. Apoptotic frequency was determined by counting the number of apoptotic cells within a population of 1000 cells as described previously (Li et al., 1996a) .
Immunoprecipitations and Western blot analyses
For Western blot analysis, protein was extracted as described previously (Li et al., 1996a) . Forty mg of protein were fractionated on 14% Tris-glycine gels (Novex, San Diego, CA, USA) for PCNA, c-Fos, and c-Jun analyses. Eighty mg of protein were fractionated on 14% Tris-glycine gels (Novex) for cyclin D1, cyclin E, E2F-1, and cdk-2 analyses. Twenty mg of protein were fractionated on 14% Tris-glycine gels (Novex) for Bcl-x long , Bax, and Bag-1. Proteins were transferred onto poly vinlidene di¯uoride (DVDF) membrane using a NOVEX Western blot transfer apparatus. After transfer and blocking with buer (5% nonfat milk/20 mM Tris base, pH 7.6/137 mM NACl) for 1 h at room temperature, the membranes were incubated with either anti-cyclin D1 (#06 ± 137, 1 : 1000 dilution, Upstate Biotechnology, Lake Placid, NY, USA), anti-cyclin E (#06 ± 459, 1 : 1000 dilution, Upstate Biotechnology), anti-cdk-2 (#sc-163, 1 : 500 dilution, Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-E2F1 (#sc-193, 1 : 500 dilution, Santa Cruz Biotechnology), anti-PCNA (#sc-56, 1 : 500 dilution, Santa Cruz Biotechnology), anti-c-Fos 
Cell cycle analysis
DNA¯ow cytometry was performed on paran embedded tissue samples. Three 50 microns sections were cut from each sample for DNA analysis (Demeril et al., 1996) . Nuclear suspensions were made using a modi®cation of Hedley's method (Hedley et al., 1983) . Tissue sections were initially deparanized in xylene for two 50 min intervals at 258C. Rehydration is accomplished by two treatments in decreasing concentrations of ethanol (100, 95, 70 and 50%) ending with deionized water. A 50 min incubation step at to 258C is required for each ethanol concentration. To make a single cell suspension, the sample is treated with a 0.5% pepsin solution (Sigma) at 378C for 30 min. The ®nal nuclear suspension is stained with propidium iodide using the Vindelov technique (Vindelov et al., 1983) . DNA¯ow analysis is performed on a FACScan¯ow cytometer (Becton Dickinson, San Jose, CA, USA). Approximately 20 000 events are collected per sample, and the parameters used for gating are FL2-W versus VL2-A. A tissue was considered diploid if only one G0/G1 peak was identi®ed. Tetraploid tissue exhibited a large dominant peak in the 4N region of the DNA histogram. If G0/G1 peaks were identi®ed between the 2N and 4N region of the DNA histogram, the tissue was designated as having a DNA aneuploid stem line. DNA cell cycle analysis was performed using Mod®t LT software (Verity Software, Topsham, ME, USA). Two 4 microns sections are requested (before and after DNA analysis) as histologic adequacy checks.
Labeling index using BrdU
BrdU labeling studies were performed on two non-transgenic control and two WAP-TAg transgenic mice at day 18 of pregnancy. BrdU (Amersham) was injected intraperitioneally (1 ml/100 g body weight). Mice were euthanized 2 h later and both fourth (inguinal) mammary glands were collected for analysis. The mammary tissue was ®xed overnight in 10% neutral buered formalin at 48C. Tissues were embedded in paran, sectioned at 5 microns, and mounted on glass slides. BrdU-labeled mammary epithelial cells were detected using a BrdU staining kit (Zymed Laboratories, Inc., San Francisco, CA, USA) with all procedures performed at room temperature. Tissue sections were deparanized in xylene, then rehydrated in a graded series of alcohol, and quenched with 3% H 2 O 2 in absolute methanol for 10 min at room temperature. Sections were then washed with phosphate buered saline (PBS) and the tissue was digested with proteinase-K (20 mg/ml PBS) for 15 min. The sections were washed in distilled H 2 O and then denatured in 4N HCl for 20 min. After washing with PBS and incubating with blocking solution (BrdU Staining Kit, Zymed) for 10 min, the tissue sections were incubated with the monoclonal antiBrdU for 40 min. Slides were then washed in PBS followed by incubation with streptavidin-peroxidase for 10 min. Sections were washed again in PBS followed by incubation with the chromogen, diaminobenzidine (DAB), for approximately 3 min. After washing with distilled H 2 O, tissues were counterstained with hematoxylin and viewed by light microscopy.
Statistical analyses
Cell cycle analyses Data were analysed using a one-way analysis of variance. The root transformation of raw data was used for analysis of the percentage distribution of cells in the cell cycle. P50.05 was considered signi®cant.
Results are presented as arithmetic means+s.e.m. of nontransformed data.
Time to ®rst palpable tumor, tumor volume, and number of tumors Means and standard deviations were calculated and paired t-tests performed using Stat View 5.4 (Abacus Concepts, Inc., Berkeley, CA, USA). P40.05 was considered signi®cant.
Survival curves of glucocorticoid exposed and control mice Tumor incidence curves were compared using the log-rank test utilizing Prism, version 2.0 (GraphPad Software, Inc., San Diego, CA, USA). P50.05 was considered signi®cant.
Abbreviations WAP, whey acidic protein; TAg, Simian virus 40 large T antigen; WAP-TAg, a transgenic mouse model of breast cancer progression in which TAg expression is targeted to mammary epithelial cells using the WAP promoter; pRb, Retinoblastoma protein; H&E, hematoxylin and eosin; PCNA, proliferating cell nuclear antigen; PBS, phosphate buered saline; DAB, diaminobenzidine; WT, wild-type nontransgenic control mice; ovx; ovariectomy; wk, weeks; PCR, polymerase chain reaction; DMBA, dimethylbenz(a)anthracene; TGF-b, transforming growth factor-b.
